Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Familial ependymoma × Etoposide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 61 Lymphoma, Non-Hodgkin 44 Lymphoma, Large B-Cell, Diffuse 41 Precursor Cell Lymphoblastic Leukemia-Lymphoma 38 Hodgkin Disease 38 Leukemia, Myeloid, Acute 36 Leukemia 34 Small Cell Lung Carcinoma 33 Burkitt Lymphoma 26 Lymphoma, Follicular 25 Lymphoma, Mantle-Cell 24 Lung Neoplasms 18 Carcinoma, Non-Small-Cell Lung 17 Multiple Myeloma 15 Lymphoma, Large-Cell, Immunoblastic 15 Lymphoma, Large-Cell, Anaplastic 14 Leukemia, Lymphocytic, Chronic, B-Cell 14 Congenital Abnormalities 14 Recurrence 13 Lymphoma, B-Cell, Marginal Zone 13 Neuroblastoma 12 Neoplasms 12 Lymphoma, B-Cell 12 Myelodysplastic Syndromes 11 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10 Immunoblastic Lymphadenopathy 10 Sarcoma 9 Myeloproliferative Disorders 9 Lymphoma, T-Cell 9 Waldenstrom Macroglobulinemia 8

Interventions

Magnetic Resonance Spectroscopy 2 Everolimus 2 Erlotinib Hydrochloride 2 ribociclib 1 palbociclib 1 olaparib 1 etoposide phosphate 1 erdafitinib 1 X-Rays 1 Sunitinib 1 Specimen Handling 1 Radiotherapy 1 Phantoms, Imaging 1 Nuclear Medicine Department, Hospital 1 N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 1 Microarray Analysis 1 Lapatinib 1 Irinotecan 1 Immunologic Techniques 1 Immunohistochemistry 1 Immunoglobulin G 1 Ifosfamide 1 Fluorodeoxyglucose F18 1 Etoposide 1 Donepezil 1 Disulfides 1 Dasatinib 1 Cyproheptadine 1 Carboplatin 1 Blotting, Western 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01032070 2024-12-12

PETEY

Astellas Pharma Inc

Phase 2 Terminated

25 enrolled 23 charts

Familial ependymoma, Ependymoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡